Systematic review and meta-analysis of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer.

Victor Hugo Fonseca de JesusMarcos P G CamandarobaVinicius F CalsavaraRachel P Riechelmann

Published in: Therapeutic advances in medical oncology (2020)

Our study suggests gemcitabine-based chemotherapy likely outperforms best supportive care after FOLFIRINOX in advanced pancreatic cancer. Also, gemcitabine plus nab-paclitaxel seems to be more active than single-agent gemcitabine (CRD42018100421).

Keyphrases

locally advanced
rectal cancer
squamous cell carcinoma
radiation therapy
healthcare
palliative care
pain management
health insurance
chemotherapy induced